Primary |
Intentional Overdose |
36.4% |
Premedication |
18.2% |
Chemotherapy |
9.1% |
Hypertension |
9.1% |
Crohn's Disease |
4.5% |
Hypersensitivity |
4.5% |
Lymphocytic Leukaemia |
4.5% |
Prophylaxis |
4.5% |
Prophylaxis Of Nausea And Vomiting |
4.5% |
Psoriasis |
4.5% |
|
Urticaria |
25.0% |
Feeling Hot |
12.5% |
Loss Of Consciousness |
12.5% |
Presyncope |
12.5% |
Sopor |
12.5% |
Syncope |
12.5% |
Tremor |
12.5% |
|
Secondary |
Premedication |
31.8% |
Drug Use For Unknown Indication |
20.5% |
Product Used For Unknown Indication |
20.5% |
Breast Cancer |
9.1% |
Haematotoxicity |
6.8% |
Colon Cancer |
2.3% |
Crohn's Disease |
2.3% |
Dermatitis |
2.3% |
Rash |
2.3% |
Vulval Disorder |
2.3% |
|
Urticaria |
18.2% |
Visual Field Defect |
18.2% |
Vomiting |
18.2% |
Hepatic Steatosis |
9.1% |
Hypotension |
9.1% |
Swelling |
9.1% |
Throat Tightness |
9.1% |
Thrombocytopenia |
9.1% |
|
Concomitant |
Premedication |
29.3% |
Crohn's Disease |
16.4% |
Product Used For Unknown Indication |
12.4% |
Drug Use For Unknown Indication |
9.4% |
Non-hodgkin's Lymphoma |
7.2% |
Breast Cancer |
5.5% |
Chronic Lymphocytic Leukaemia |
2.9% |
Colon Cancer |
2.7% |
Colorectal Cancer |
1.9% |
Prophylaxis |
1.8% |
Hypertension |
1.5% |
Prophylaxis Of Nausea And Vomiting |
1.3% |
Prophylaxis Against Gastrointestinal Ulcer |
1.2% |
Antiemetic Supportive Care |
1.2% |
Ovarian Cancer |
1.1% |
Chemotherapy |
1.0% |
Glycogen Storage Disease Type Ii |
0.9% |
Stomatitis |
0.9% |
Oropharyngeal Cancer Stage Unspecified |
0.7% |
Gastrointestinal Disorder Therapy |
0.7% |
|
Loss Of Consciousness |
9.9% |
Pyrexia |
9.2% |
Rash |
7.6% |
Septic Shock |
7.6% |
Tachycardia |
6.9% |
Thyroid Cancer |
6.1% |
Urticaria |
6.1% |
Thrombocytopenia |
5.3% |
Vomiting |
4.6% |
Dyspnoea |
3.8% |
Oxygen Saturation Decreased |
3.8% |
Syncope |
3.8% |
Urinary Tract Infection |
3.8% |
Erythema |
3.1% |
Hyperamylasaemia |
3.1% |
Hypocalcaemia |
3.1% |
Nausea |
3.1% |
Pneumonia |
3.1% |
Pneumonitis |
3.1% |
Pruritus |
3.1% |
|